Is p53 and heat shock protein 70 expression a useful parameter for preoperative hyperthermoradiation therapy in advanced rectal carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 74, 2007, Pages 367-372

  Takeuchi, Kunio ^a,b   Nakajima, Masanobu ^a   Miyazaki, Tatsuya ^a   Ide, Munenori ^a   Asao, Takayuki ^a   Fujita, Kin'ichi ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Tone Chuo Hospital   (Japan)

Author keywords

Advanced rectal carcinoma; Heat shock protein 70; Hyperthermoradiation therapy; p53

Indexed keywords

HEAT SHOCK PROTEIN 70; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM BIOPSY; RECTUM CARCINOMA; RECTUM SURGERY;

ADULT; AGED; BIOPSY; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; MIDDLE AGED; NECROSIS; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; RECTUM; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248208028     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ishikawa D, Yamaguchi T, Yoshikawa Y, Sawai K, Takahashi T: Prognostic evaluation of advanced cancer in the lower rectum with radiation, intraluminal hyperhtermia, and 5-fluorouracil suppository. Am J Surg 1996; 171:346-350.
2. Rau B, Wust P, Riess H, Schlag PM: Radiochemotherapy plus hyperthermia in rectal carcinoma. Schweiz Rundsch Med. Prax, 2001; 90:587-592.
3. Fujita K, Kuwano H, Asao T, Nakamura J, Hirayama I, Morinaga N, Masuda N, Ide M, Sakurai H, Kurosaki H, Tamura J, Mitsuhashi N: The combined effect of preoperative hyperthermia and radiation therapy on advanced rectal carcinoma. Jpn J Hyperthermic Oncol 2001; 17:151-157.
4. Abe T, Sakaguchi Y, Ohno S, Ikeda Y, Kitamura K, Maehara Y, Sugimachi K: Apoptosis and p53 overexpression in human rectal cancer; relationship with response to hyperthermo-chemo-radiotherapy. Anti Cancer Res 2001; 21:2115-2120.
5. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54:5824-5830.
6. Tsang NM, Nagasawa H, Li C, Little JB: Abrogation of p53 function by transfection of HPV 16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 1995; 10:2403-2408.
7. Namba H, Hara T, Tukazaki T, Migita K, Ishikawa N, Ito K, Nagataki S, Yamashita S: Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/CIP1 pathway in human thyroid cells. Cancer Res 1995; 55:2075-2080.
8. Rau B, Gaestel M, Wust P, Stahl J, Mansmann U, Schlag PM, Benndorf R: Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heat-shock response. Radiation Res 1999; 151:479-488.
9. Nakajima M, Kuwano H, Miyazaki T, Masuda N, Kato H: Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Letter 2002; 178:99-106.
10. Lazaris AC, Theodorpoulos GE, Davaris PS, Panoussopoulos D, Nakopulos L, Kittas C, Golematis BC: Heat shock protein 70 and HLA-DR molecules tissue expression: prognostic implication in colorectal cancer. Dis Colon Rectum 1995; 38:739-745.
11. Lazaris AC, Chatzigianni EB, Panoussopoulos D, Tzimas GN, Davaris PS, Golematis BC: Proliferating cell nuclear antigen and heat shock protein 70 immunocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 1997; 43:43-51.
12. Santarosa M, Favaro D, Quaia M, Galligioni E: Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997; 33:873-877.
13. Furuta K, Konishi F, Kanazawa K, Sito K, Sunagawa T: Synergistic effects of hyperthermia in preoperative radiochemotherapy for rectal carcinoma. Dis Colon Rectum 1997; 40:1303-1312.
14. Ohno S, Tomoda M, Tomisaki S, Kitamura K, Mori M, Maehara Y, Sugimachi K: Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum. Dis Colon Rectum 1997; 40:401-406.
15. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G: Increased p53 protein content of colorectal tumors correlates with poor survival. Br J Cancer 1992; 66:758-764.
16. Tominaga O, Hamelin R, Trouvat V, Salmon RJ, Lesec G, Thomas G, Remvikos Y: Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 1993; 8:2653-2658.
17. Tominaga O, Hamelin R, Remvikos Y, Salmon RJ, Thomas G: p53 from basic research to clinical application. Crit Rev Oncog 1992; 3:257-282.
18. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell by wild-type p53. Science 1990; 249:912-915.
19. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
20. Fu C-G, Tominaga O, Nagawa H, Nita ME, Masaki T, Ishimaru G, Higuchi Y, Tsuruo T, Muto T: Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998; 41:68-74.
21. Bree C van, Maat B van der, Ceha HM, Franken NAP, Haneman J: Inactivation of p53 and pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis. J Cancer Res Clin Oncol 1999; 125:549-555.
22. Sakakura C, Koide K, Ichikawa D, Wakasa T, Shirasu M, Kimura A, Taniguchi H, Hagiwara A, Yamaguchi T, Inazawa J, Abe T, Takahashi T, Otsuji E: Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. Br J Cancer 1998; 77:159-166.
23. van Bree C, Franken NA, Snel FA, Haveman J, Bakker PJ: Wild-type p53-function is not required for hyperthermia-enhanced cytotoxicity of cisplatin. Int J Hyperthermia 2001; 17:337-346.
24. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79:329-339.
25. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993; 53:3667-3669.
26. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Nat Acad Sci 1992; 89:3439-3442.